Neurocrine Biosciences (NASDAQ:NBIX) said the FDA has accepted its two new drug applications for priority review for its drug crinecerfont in the treatment of pediatric and adult patients with congenital adrenal hyperplasia, a rare endocrine disorder.
https://seekingalpha.com/news/4121247-fda-sets-target-action-dates-for-neurocrine-drug-applications